🇺🇸 FDA
Patent

US 12319916

Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs

granted A61PA61P13/00

Quick answer

US patent 12319916 (Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs) held by CAMP4 Therapeutics Corporation expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CAMP4 Therapeutics Corporation
Grant date
Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P13/00